Press Releases

Apr 14, 2020

Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests

Apr 02, 2020

MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH

Mar 16, 2020

Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation

Mar 16, 2020

Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay

Feb 26, 2020

Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers

Feb 19, 2020

Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

Feb 07, 2020

Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance

Jan 27, 2020

Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak

Jan 23, 2020

Meridian Launched a New High-Fidelity Polymerase to Offer Robust Amplification for NGS and PCR Applications

Jan 15, 2020

Meridian Bioscience to Hold First Quarter 2020 Financial Results Conference Call on February 7, 2020

Nov 07, 2019

Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2019 Operating Results and Provides Fiscal 2020 Guidance

Nov 06, 2019

Meridian submits Curian™ analyzer and the Curian™ HpSA assay to the FDA

Oct 16, 2019

Meridian Bioscience to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on November 7, 2019

Jul 30, 2019

Meridian Bioscience Reports Third Quarter 2019 Operating Results

Jul 10, 2019

Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019

Jun 03, 2019

Meridian Bioscience Announces Closing of Transaction to Acquire Business of GenePOC

Apr 30, 2019

Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition

Apr 30, 2019

Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform

Apr 30, 2019

Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition

Apr 30, 2019

Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform

Innerpage

Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests

MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH

Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation

Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay

Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers

Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance

Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak

Meridian Launched a New High-Fidelity Polymerase to Offer Robust Amplification for NGS and PCR Applications

Meridian Bioscience to Hold First Quarter 2020 Financial Results Conference Call on February 7, 2020

Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2019 Operating Results and Provides Fiscal 2020 Guidance

Meridian submits Curian™ analyzer and the Curian™ HpSA assay to the FDA

Meridian Bioscience to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on November 7, 2019

Meridian Bioscience Reports Third Quarter 2019 Operating Results

Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019

Meridian Bioscience Announces Closing of Transaction to Acquire Business of GenePOC

Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition

Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform

Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition

Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform